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Neovascular age-related macular degeneration (AMD) 
is a leading cause of central vision loss in the elderly [1,2], 
AMD is a complex disease in that it involves multiple 
different cell types and many signaling pathways, including 
those involving oxidation, inflammation, and angiogenesis 
[3-6]. Currently, antiangiogenic agents that interfere with the 
bioactivity of vascular endothelial growth factor (VEGF) are 
the standard of care for neovascular AMD based on evidence 
from human clinical trials [7,8], but these agents are effective 
in about 40% of eyes. There are several potential reasons for 
this, and one is that other factors, such as those involved in 
oxidative or inflammatory signaling mechanisms, are also 
important and may be playing a role in the pathophysiology. 
Experimental animal models of neovascular AMD induced 
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Purpose: Inflammation, oxidative stress, and angiogenesis have been proposed to interact in age-related macular de-
generation. It has been postulated that external stimuli that cause oxidative stress can increase production of vascular 
endothelial growth factor (VEGF) in retinal pigment epithelial (RPE) cells. In this study, we tested the hypothesis that 
the inflammatory cytokine, tumor necrosis factor alpha (TNF-α), contributed to choroidal neovascularization (CNV) 
by upregulating VEGF in RPE through intracellular reactive oxygen species (ROS)-dependent signaling and sought to 
understand the mechanisms involved.
Methods: In a murine laser-induced CNV model, 7 days after laser treatment and intravitreal neutralizing mouse TNF-α 
antibody or isotype immunoglobulin G (IgG) control, the following measurements were made: 1) TNF-α protein and 
VEGF protein in RPE/choroids with western blot, 2) CNV volume in RPE/choroidal flatmounts, and 3) semiquantifica-
tion of oxidized phospholipids stained with E06 antibody within CNV with immunohistochemistry (IHC). In cultured 
human RPE cells treated with TNF-α or PBS control, 1) ROS generation was measured using the 2’,7’-dichlorodihydro-
fluorescein diacetate (DCFDA) fluorescence assay, and 2) NOX4 protein and VEGF protein or mRNA were measured 
with western blot or quantitative real-time PCR in cells pretreated with apocynin or nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH) inhibitor, VAS 2870, or transfected with p22phox siRNA, and each was compared to its 
appropriate control. Western blots of phosphorylated p65 (p-p65), total p65 and β-actin, and quantitative real-time PCR 
of VEGF mRNA were measured in human RPE cells treated with TNF-α and pretreatment with the nuclear factor kappa 
B inhibitor, Bay 11–7082 or control. Western blots of β-catenin, VEGF, and p22phox and coimmunoprecipitation of 
β-catenin and T-cell transcriptional factor were performed in human RPE cells treated with TNF-α following pretreat-
ment with β-catenin transcriptional inhibitors, XAV939 or JW67, or transfection with p22phox siRNA and compared 
to appropriate controls.
Results: Compared to the non-lasered control, TNF-α and VEGF protein were increased in the RPE/choroids in a murine 
laser-induced CNV model (p<0.05). An intravitreal neutralizing antibody to mouse TNF-α reduced CNV volume, and 
VEGF protein in the RPE/choroids (p<0.01) and oxidized phospholipids within CNV compared to IgG control (p<0.05). 
In cultured RPE cells and compared to controls, TNF-α induced ROS generation and increased activation of NOX4, 
an isoform of NADPH oxidase; both were prevented by pretreatment with the apocynin or VAS2870 or knockdown 
of p22phox, a subunit of NADPH oxidase. TNF-α treatment increased VEGF expression (p<0.001) and the formation 
of a transcriptional complex of β-catenin and T-cell transcriptional factor; both were prevented by pretreatment with 
apocynin or knockdown of p22phox. Inhibition of β-catenin by XAV939, but not the nuclear factor kappa B inhibitor, 
Bay 11–7082, prevented TNF-α-induced VEGF upregulation.
Conclusions: Our results support the thinking that TNF-α contributes to CNV by upregulating VEGF production in RPE 
cells through ROS-dependent activation of β-catenin signaling. These results provide mechanisms of crosstalk between 
inflammatory mediator, TNF-α, and ROS in RPE cells.
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by laser show reduced, but not abolished, choroidal neovas-
cularization (CNV) from antioxidants or through silencing 
or knockout of genes involved in oxidative signaling [9,10]. 
Antioxidants also slow the progression of AMD in human 
clinical trials [11].
In animal models of laser-induced CNV, macrophages 
recruited to the outer retina release inflammatory cytokines 
to contribute to CNV volume [12]. Macrophages release 
inflammatory cytokines that have been found in human 
specimens of advanced AMD [13,14]. However, the evidence 
for inhibiting inflammation broadly through steroids or 
inhibitors of cytokines, is less clear [15-17].
The cytokine, tumor necrosis factor alpha (TNF-α), has 
been associated with advanced forms of AMD [14]. Elevated 
systemic TNF-α was found in patients with AMD and a 
variant of the complement factor (CFH) Y402H polymor-
phism, which is highly correlated with AMD [13]. In neovas-
cular AMD, TNF-α was found in macrophages within surgi-
cally removed CNV from patients with neovascular AMD 
[14]. TNF-α and reactive oxygen species (ROS) have been 
associated with CNV in laser-induced models [3]. However, in 
vitro, TNF-α decreased VEGF secretion in a highly polarized 
layer of RPE cells with intact barriers, and only increased 
VEGF expression in non-polarized RPE cells, which had 
reduced barrier integrity [18]. To gain insight into the inter-
actions between oxidative and inflammatory signaling on 
RPE cell-induced VEGF expression and the development 
of CNV, we tested the hypothesis that TNF-α upregulates 
VEGF expression in RPE cells via ROS-dependent signaling. 
We found that TNF-α activated NADPH oxidase to generate 
ROS that then triggered β-catenin transcriptional activation 
to increase VEGF expression in RPE cells and in a laser-
induced CNV model.
METHODS
Animals: Five- to eight-week-old C57Bl/6 wild-type mice 
were used in these studies. All animal procedures were 
conducted in accordance with the University of Utah Guide 
for the Care and Use of Laboratory Animals and the Associa-
tion for Research in Vision and Ophthalmology Statement 
for the Use of Animals in Ophthalmic and Vision Research.
Laser-induced CNV model and injections: The laser-induced 
CNV model was performed as previously described [10]. 
Intraperitoneal injections of 100 mg/kg ketamine (Hospira, 
Inc., Lake Forest, IL) and 20 mg/kg xylazine (AnaSed Lloyd 
Laboratories, Shenandoah, IA) were used for anesthesia. 
Following mydriasis with 1% tropicamide ophthalmic solu-
tion (Bausch & Lomb, Tampa, FL), the mouse was secured 
on a stage, and a coupling agent, GenTeal (Alcon, Fort Worth, 
TX), was applied to the cornea. Laser photocoagulation was 
performed with a 532 nm Phoenix Image-Guided Laser 
System (Phoenix Micron IV, Pleasanton, CA) using the 
settings of 400 mW intensity and 100 ms duration. Four to 
five laser spots per eye were applied approximately 2 disc 
diameters from the optic nerve, avoiding major vessels. 
Disruption of Bruch’s membrane was confirmed by the 
appearance of a cavitation bubble. Right after laser injury, 
using a MICROLITER syringe (Hamilton Company, Reno, 
NV), an intravitreal injection of total volume of 1 µl of 
neutralizing anti-mouse TNF-α antibody (TNF-α Ab, 50 ng/
ml, R&D Systems, Minneapolis, MN) or control, isotype 
immunoglobulin G (IgG, 50 ng/ml, R & D Systems). Both 
eyes of each mouse were lasered and injected with the same 
type of injection. Seven days after the laser treatment, the 
mice were euthanized by CO2 exposure, and one eye from 
each mouse was collected for RPE/choroidal f latmount 
analysis and the fellow eye for protein by immunostaining of 
the retinal cryosections or western blot analysis. Each group 
included both eyes of at least eight mice.
Analysis of CNV volume in RPE/choroidal f latmounts: 
Eyes were first fixed in 4% paraformaldehyde (Electron 
Microscopy Sciences [EMS], Hatfield, PA) for 1 h. After 
the cornea was removed, the lens, retina and vitreous, and 
posterior eyecups of the RPE/choroid/sclera were dissected. 
The eyecups were stained with Alexa Fluor 568-conju-
gated isolectin B4 (Invitrogen, Carlsbad, CA, Cat # I21412) 
overnight at 4 °C to label invading choroidal vessels. The 
eyecups were then flattened by cutting radial incisions and 
f latmounted on a microscope slide with Fluoromount G 
(Southern Biotech, Birmingham, AL) for confocal imaging. 
The flatmounts were imaged by taking optical Z-sections 
at3 µm increments with a confocal microscope (FV1000, 
Olympus, Melville, NY). The volume (µm3) of each lesion of 
CNV was measured by computerized image analysis using 
software provided with the microscope. Lesions with obvious 
hemorrhage or bridging CNV were excluded. Each CNV spot 
was considered an independent data point. For each condi-
tion, at least 30 spots were analyzed from eight mice.
Retinal and RPE/choroidal section preparation and immu-
nostaining of OxPLs: Eyes were first fixed in 4% paraformal-
dehyde for 1 h, and then the corneas and lenses were removed. 
Eyecups were incubated in 30% sucrose overnight and frozen 
at −80 °C after immersion in optimal cutting temperature 
compound (OCT: Tissue Tek; EMS). The eyecups were cut 
into 12 µm cryosections. Sections were incubated with E06 
monoclonal antibody (1:100, Avanti POLAR LIPIDS, Inc., 
Alabaster, Alabama, Cat # 330001) overnight at 4 °C. After 
rinsing, the sections were incubated for 1 h with fluorescein 
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isothiocyanate (FITC)-conjugated goat anti-mouse IgM 
(1:100, Sigma-Aldrich, St. Louis, MO, Cat # F9259), Alexa 
Fluor 568-conjugated antibody for isolectin B4 (lectin, 
1:200, Invitrogen) to stain the vessels, and Topro 3 (1:1,000, 
Life Technologies, Grand Island, NY) to stain the nuclei. 
The sections stained with no primary antibody were used 
as controls. Labeling for all sections was performed during 
the same experimental session. Images were captured using 
confocal microscopy (Olympus IX81) at 20X magnification. 
Within the sections of lectin-stained CNV, E06 labeling to 
measure oxidized phospholipids (OxPLs) was determined 
with fluorescent density using Image J. At least ten CNV 
lesions per condition were analyzed (n=6 per condition).
Cell culture: Human primary RPE cells (hRPE; Lonza, Walk-
ersville, MD) were grown in retinal pigment epithelial cell 
basal media (RtEBM, Lonza) and used from passages 3–5. In 
some experiments, the cells were pretreated with the nuclear 
factor kappa B (NF-ҡB) inhibitor, Bay 11–7082 (5 µM), or 
Wnt/beta catenin inhibitors, JW 67 (20 µM) or XAV939 
(1 µM; Tocris Bioscience, Bristol, UK), and then incubated 
with human recombinant TNF-α (20 ng/ml, R&D Systems) or 
PBS (1X, 137.93 mM NaCl, 8.06 mM NaPO4, 2.67 mM KCl, 
1.47 mM KH2PO4, pH 7.4) for further analyses.
siRNA transfection in human RPE cells: To knock down 
p22phox, RPE cells were transfected using Lipofectamine 
2000 according to the commercial protocol (Life Technolo-
gies) with siRNA targeting the human CYBA gene (Gene ID: 
1535 and OMIM 608508; p22phox) or silencer selective nega-
tive control siRNA (both from Life Technologies). Forty-eight 
hours after transfection, the cells were incubated with human 
recombinant TNF-α (20 ng/ml, R&D Systems) or PBS for 
further analysis. All experimental conditions were plated in 
triplicate.
ROS generation assay in human RPE cells: RPE cells 
were seeded into 96-well plates and infected with adeno-
viral constructs. Forty-eight hours post infection, the cells 
were loaded with 5 µM 2’,7’-dichlorofluorescein diacetate 
(DCFDA, Invitrogen) in serum-free medium for 30 min at 
37 °C. After two washes with PBS, the cells were pretreated 
with apocynin (100 µM), or NADPH oxidase inhibitor, VAS 
2870 (20 µM, EMD Millipore), or control PBS or dimethyl 
sulfoxide (DMSO) for 30 min and then incubated with TNF-α 
or control PBS for another 30 min. ROS generation was 
measured in a fluorescent plate reader (excitation at 488 nm 
and emission at 520 nm). Cells incubated with 10 µM H2O2 
were used as a positive control (n=9 per condition).
Immunoprecipitation and immunoblots: RPE cells were 
lysed in radioimmunoprecipitation assay buffer (RIPA) with 
protease inhibitor cocktail (Roche Diagnostics, Indianapolis, 
IN) and orthovanadate (Sigma-Aldrich). Lysates were clari-
fied with centrifugation at 1.61x104 ×g for 5 min at 4 °C. 
The protein concentration in the supernatant was quantified 
with bicinchoninic acid assay (BCA; Pierce, Rockford, IL). 
The total protein (500 µg in 500 µl) for each sample was 
incubated with antibody to T cell factor 1 (TCF1, 1:200, Cell 
Signaling Technology Inc., Danvers, MA) by gently rocking 
at 4 °C overnight. Ten microliters of Dynabeads protein G 
(Invitrogen) were added and incubated for an additional 1 h 
at 4 °C. The antibody/protein/agarose complex was washed 
three times with RIPA buffer and resuspended in 2X sample 
buffer. The protein complex bound to TCF1 or pan-cadherin 
was separated with NuPAGE 4% to 12% Bis-Tris Gels (Invi-
trogen) and transferred to a polyvinylidene fluoride (PVDF) 
membrane, and then incubated with antibody to β-catenin 
(1:1,000, Cell Signaling Technology Inc.) overnight at 4 °C. 
All membranes were reprobed with TCF1 or pan-cadherin to 
ensure equal protein loading.
For TNF-α, VEGF and β-catenin in the RPE/choroids or 
in the RPE cells, 20 µg of protein from each treatment was 
loaded into NuPAGE 4% to 12% Bis-Tris Gels (Invitrogen), 
transferred to a PVDF membrane, and incubated with anti-
bodies to TNF-α (1:1,000, Cell Signaling Technology Inc.), 
VEGF (1:500, Santa Cruz Biotechnology, Santa Cruz, CA), 
or β-catenin at 4 °C overnight. Densitometry analysis was 
performed on exposed films with the use of the software 
UN-SCAN-IT version 6.1 (Silk Scientific, Orem, UT). All 
experimental conditions were plated in triplicate (n=6).
RNA Isolation and qPCR analysis: Total RNA of the RPE/
choroidal tissues was extracted with TRI Reagent (Sigma-
Aldrich). RNA was quantified using a NanoDrop spectro-
photometer (Thermo Fisher Scientific, Waltham, MA). 
cDNA was generated with the use of a high-capacity cDNA 
archive kit (Life Technologies). Quantitative PCR (qPCR) was 
performed on a Mastercycler ep realplex system (Eppendorf, 
Hauppauge, NY) with the use of SYBR Green Master Mix 
(Roche Diagnostics) and primers synthesized by the core 
research facility of the University of Utah. Expression levels 
for VEGF were normalized to the mean value of the internal 
control, GAPDH. The primers (forward and reverse, respec-
tively) were mouse VEGF 5′-TGG TTC TTC ACT CCC TCA 
AAT C-3′ and 5′- GGT CTC TCT CTC TCT TCC TTG A-3′, 
and mouse GAPDH 5′-GGA GAA ACC TGC CAA GTA 
TGA-3′ and 5′-TCC TCA GTG TAG CCC AAG A-3′.
Statistical analysis: Significant differences between groups 
were determined with ANOVA with post hoc protection using 
the Bonferroni multiple comparison test. Results were the 
mean ± standard error of the mean (SEM). A minimum p 
value of less than 0.05 was considered statistically significant. 
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For animal studies, at least 30 laser spots were analyzed for 
CNV, and ten retinal sections, p<0.01 for oxidized phospho-
lipids (OxPLs) from different animals. Western blot or PCR 
analyses included six to eight retinas/condition. For analysis 
of densitometry of the immunolabeled retinas, at least three 
sections imaged at 60 μm intervals were examined/eye. For 
IHC and western blots, a total of at least three (IHC) or five 
(western blots) eyes were analyzed for each condition. For in 
vitro studies, each experimental condition included an n=6–9, 
and each experiment was performed three times.
RESULTS
TNF-α mediates CNV formation in association with increased 
VEGF expression in a murine l laser-induced CNV model: 
TNF-α (p<0.05) and VEGF (p<0.01) protein in RPE/choroid 
lysates were significantly increased 7 days after laser injury 
compared to the non-lasered controls (Figure 1A,B). Similar 
to previous studies [19], treatment with intravitreal neutral-
izing antibody to mouse TNF-α (TNF-α Ab) significantly 
reduced the volume of laser-induced CNV compared to the 
mice treated with the isotype IgG control (IgG; Figure 1C,D, 
p<0.01) To determine if reduced CNV volume was associ-
ated with reduced VEGF, we measured the VEGF protein 
in the RPE/choroids by western blot and found that in the 
mice treated with intravitreal TNF-α Ab, VEGF protein in the 
RPE/choroids was significantly decreased compared to that in 
the RPE/choroids from the mice treated with intravitreal IgG 
(Figure 1E,F, p<0.01). These results provide evidence that 
TNF-α induced CNV was associated with increased VEGF 
expression.
TNF-α induces NADPH oxidase-generated ROS at CNV 
lesions and in cultured RPE cells: We previously found that 
external sources of oxidative stress were implicated in laser-
induced CNV [10,20]. Therefore, we determined the effect 
of TNF-α on ROS generation in laser-induced CNV. We 
measured OxPLs by immunostaining with the E06 antibody. 
As shown in Figure 2A, OxPL staining was located within 
CNV, and quantification of immunofluorescence confirmed 
that OxPL staining was significantly reduced in the TNF-α 
Ab-treated mice compared to the control IgG-treated mice 
(Figure 2B, p<0.05). Additionally, ROS generation was 
measured with 2',7'-dichlorofluorescein diacetate (DCFDA) 
fluorescence in cultured human RPE cells incubated with 
different doses of recombinant human TNF-α for 30 min. 
Compared to PBS, TNF-α significantly increased ROS 
generation in a dose-dependent pattern (Figure 3A). To deter-
mine whether TNF-α-mediated ROS generation involved 
activation of NADPH oxidase, ROS were measured in RPE 
cells pretreated with apocynin (Apo) or the NADPH oxidase 
inhibitor, VAS2870 (VAS), for 30 min before stimulation with 
TNF-α. As shown in Figure 3B, pretreatment with Apo or 
VAS prevented TNF-α-induced ROS generation (p<0.001). 
We previously reported that NOX2 was involved in CNV 
pathogenesis, as evidenced by reduced CNV in laser-treated 
p47phox knockout mice compared to the wild-type mice [10]. 
We also found that VEGF-activated NOX4, an isoform of 
NADPH oxidase, mediated retinal microvascular endothelial 
cell proliferation by interacting with VEGFR2 [21]. There-
fore, we determined whether TNF-α activated NOX4 in RPE 
cells. The NOX4 protein level and activation determined by 
cobinding with p22phox were measured in RPE cells treated 
with TNF-α or PBS, and VEGF was used as a positive 
control. As shown in Figure 3, compared to PBS, overnight 
treatment with TNF-α increased the NOX4 protein level 
(Figure 3C) and activation (Figure 3D,E, p<0.05). NADPH 
oxidase-dependent ROS generation was further determined 
in the RPE cells transfected with siRNA targeting human 
p22phox, a subunit required for NADPH oxidase activation 
by NOX2 or NOX4. Compared to the control siRNA and PBS 
treatment, knockdown of p22phox prevented ROS generation 
in RPE cells treated with PBS p<0.05 or TNF-α (p<0.001; 
Figure 3F). These results provide evidence that activation of 
NADPH oxidase was likely a source of ROS generation in 
the RPE cells and that TNF-α-mediated ROS in the RPE cells 
was generated through activation of NADPH oxidase.
TNF-α upregulates VEGF expression in RPE cells via ROS-
dependent activation of β-catenin: To determine whether 
TNF-α affects VEGF expression in RPE cells, VEGF was 
measured with western blot after treatment of the RPE cells 
with TNF-α for 0, 3, 6, or 12 h. As shown in Figure 4A, 
TNF-α increased VEGF protein level as early as 3 h after 
TNF-α treatment and remained upregulated at 12 h compared 
to control. To determine whether ROS signaling was involved 
in TNF-α-mediated VEGF upregulation, RPE cells were 
pretreated with apocynin for 30 min to quench ROS before 
incubation with TNF-α overnight and then analyzed for 
VEGF mRNA with quantitative PCR. TNF-α-induced VEGF 
mRNA was significantly inhibited by apocynin treatment 
(Figure 4B, p<0.05), suggesting that TNF-α upregulates 
VEGF expression in RPE cells via ROS-dependent signaling.
Activation of NF-ҡB is a classic inflammatory signaling 
pathway mediated by TNF-α. Therefore, we tested whether 
inhibition of NF-ҡB would inhibit TNF-α-mediated VEGF 
expression in RPE cells. In RPE cells, TNF-α activated 
NF-ҡB determined by increased p-p65, but inhibition of 
TNF-α-induced NF-ҡB activation by Bay 11–7082 (Figure 
5A) did not affect TNF-α-induced VEGF upregulation 
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Figure 1. TNF-α mediates CNV formation in association with VEGF expression in a murine model of laser-induced CNV. A: Representative 
images of western blot of tumor necrosis factor alpha (TNF-α) and vascular endothelial growth factor (VEGF) protein in RPE/choroids of 
C57Bl/6 6-week-old mice without laser treatment (non-lasered) or 7 days after laser treatment. B: Quantification of densitometry (lasered; 
*p<0.05, **p<0.01 versus non-lasered). C: Representative images of choroidal neovascularization (CNV) volume. D: Quantification of CNV 
volume. E: Representative images of western blot of VEGF in RPE/choroids of mice injected with isotype immunoglobulin G (IgG, 50 ng) 
or neutralizing TNF-α antibody. F: Quantification of densitometry (TNF-α Ab, 50 ng; ††p<0.01 versus IgG).
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Figure 2. TNF-α induces ROS generation within multiple cell types within CNV lesions. A: Immunostaining for oxidized phospholipids 
(OxPLs) in retinal/choroidal cryosections. Images were taken in the regions with choroidal neovascularization (CNV) at 20X and 40X 
magnification. Top panel: 20X, bottom panel: 40X. Green, OxPL; Red, lectin; Gray, Topro 3. B: Quantification of densitometry of OxPL 
immunofluorescence at CNV lesions of mice injected with isotype immunoglobulin G (IgG, 50 ng) or neutralizing tumor necrosis factor 
alpha (TNF-α) antibody (TNF-α Ab, 50 ng; *p<0.05 versus IgG).
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Figure 3. TNF-α induces ROS generation in human RPE cells by activating NADPH oxidase. A: Reactive oxygen species (ROS) generation 
measured with 2',7'-dichlorofluorescein diacetate (DCFDA) fluorescence in human RPE cells treated with recombinant human tumor necrosis 
factor alpha (TNF-α) at various concentrations for 30 min (***p<0.001 versus PBS; †††p<0.001 versus TNF-α at 10 ng/ml; ‡‡p<0.01 versus 
TNF-α at 30 ng/ml). B: ROS generation measured with DCFDA fluorescence in human RPE cells pretreated with apocynin (Apo, 100 µM) 
and VAS 2870 (VAS, 20 µM) for 30 min before incubation with TNF-α (20 ng/ml) for an additional 30 min (***p<0.001 versus vehicle; 
†††p<0.001 versus TNF-α). C: Western blot of NOX4. D: Representative gel images of coimmunoprecipitation of NOX4 and p22phox in RPE 
cells treated with TNF-α or vascular endothelial growth factor (VEGF) overnight (*p<0.05 versus PBS). E: Quantification of densitometry 
in RPE cells treated with TNF-α or VEGF overnight (*p<0.05 versus PBS). F: ROS generation measured with DCFDA fluorescence in 
human RPE cells) with p22phox knockdown by siRNA transfection and incubated with TNF-α (20 ng/ml) for 30 min (*p<0.05 versus PBS 
of ConsiRNA; †††p<0.001 versus TNF-α of ConsiRNA).
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(Figure 5B). This failed to show that the NF-ҡB signaling 
pathway was involved in TNFα-induced VEGF upregulation.
Wnt/β-catenin signaling is implicated in inflammation. 
Activated β-catenin translocates to the nucleus and regulates 
gene expression by forming a complex with tissue cell factor 
(TCF)/lymphoid enhancing factor (LEF) transcriptional 
factors. Therefore, we determined whether Wnt/β-catenin 
signaling was involved in TNF-α-mediated VEGF upregula-
tion. RPE cells were pretreated with JW67 [22] or XAV939 
[23], inhibitors of Wnt/β-catenin signaling, before incubation 
with TNF-α, and the β-catenin and VEGF protein levels were 
measured. As shown in Figure 6A, β-catenin was increased 
by TNF-α as early as 1 h after treatment and was inhibited 
by pretreatment with XAV939, but not JW67. In the same 
cell lysates, VEGF protein was increased by TNF-α as early 
as 1 h after treatment and remained upregulated at 6 h after 
treatment. Inhibition of Wnt/β-catenin signaling by XAV939 
prevented VEGF upregulation by TNF-α (Figure 6B). To 
determine the mechanism, co-immunoprecipitation of beta-
catenin and TCF1 was determined. As shown in Figure 6, 
TNF-α treatment induced greater coimmunoprecipitated 
β-catenin and TCF1, and this was inhibited by pretreatment 
with apocynin or XAV939 (Figure 6C) or by knockdown of 
p22phox (Figure 6D). These findings provide evidence that 
TNFα led to VEGF upregulation through β catenin/TCF1 
transcription.
Altogether, the results in Figure 6 and Figure 7 provide 
evidence that TNF-α upregulates VEGF expression in 
RPE cells via ROS-dependent activation of Wnt/β-catenin 
signaling, independent of NF-ҡB. These data provide 
evidence that TNF-α-mediated NADPH oxidase-generated 
ROS trigger Wnt/β-catenin activation and β-catenin 
Figure 4. TNF-α upregulates VEGF 
expression in RPE cells via ROS-
dependent signaling. A: Western 
blot of vascular endothelial growth 
factor (VEGF) in RPE cells treated 
with tumor necrosis factor alpha 
(TNF-α; 20 ng/ml) for 3, 6, or 12 
h. B: Quantitative PCR of VEGF 
mRNA in RPE cells pretreated with 
apocynin (100 µM) or control for 30 
min before incubation with TNF-α 
(20 ng/ml) for an additional 12 h 
(***p<0.001 versus PBS of control; 
†p<0.05 versus TNF-α of control).
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translocation and binding with TCF1 that led to increased 
VEGF expression.
DISCUSSION
Neovascular AMD is often associated with CNV, in which 
blood vessels originate from the choriocapillaris and grow 
into Bruch’s membrane, under the RPE or into the neural 
retina [24]. VEGF plays a fundamental role in the develop-
ment of CNV, and anti-VEGF agents have been widely used 
for treatment of neovascular AMD, yielding improved vision 
acuity in about 40% of patients with repeated monthly injec-
tions. However, factors other than VEGF are involved in 
AMD. Therefore, understanding the role of these mechanisms 
may and lead to better treatments for neovascular AMD.
Cumulative evidence suggests that oxidative stress and 
inflammation play important roles in the pathogenesis of 
neovascular AMD [3,25]. However, the mechanisms involved 
in how these stresses lead to pathologic biologic events and 
the possible crosstalk between signaling pathways remain 
incompletely understood. ROS cause cell damage directly but 
can also trigger intracellular signal transduction that leads to 
various outcomes in different cell types involved in AMD. 
In this report, we studied the effects of the inflammatory 
cytokine, TNF-α, on RPE-induced VEGF expression and 
the interactions of inflammatory and oxidative signaling in 
angiogenesis, as evidenced by the development of CNV.
Using a murine model of laser-induced CNV, we found 
laser injury induced TNF-α expression in temporal asso-
ciation with the development of CNV. Inhibition of TNF-α 
bioactivity by an intravitreal injection of a neutralizing 
antibody to murine TNF-α reduced CNV volume in associa-
tion with decreased VEGF expression in the RPE/choroids, 
compared to control. These results provide evidence that 
TNF-α contributed to CNV by increasing VEGF expression. 
VEGF is upregulated by hypoxia- or ROS-induced hypoxia 
Figure 5. TNF-α-mediated NF-ҡB 
activation is not involved in VEGF 
upregulation in human RPE cells. 
A: Western blots of p-p65, total p65, 
and β-actin. B: Real-time PCR of 
vascular endothelial growth factor 
(VEGF) in RPE cells pretreated 
with Bay 11–7082 (5 µM) or control 
dimethyl sulfoxide (DMSO) for 30 
min before incubation with tumor 
necrosis factor alpha (TNF-α; 20 
ng/ml) for an additional (A) 5, 15, 
or 30 min or (B) 12 h (***p<0.001 
versus PBS of control; †††p<0.001 
versus PBS of Bay 11–7082).
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inducible factor 1 alpha stabilization [26,27]. We found that 
inhibition of TNF-α activity decreased the accumulation of 
oxidized lipoproteins within CNV lesions, suggesting an 
association between inflammatory and oxidative signaling 
pathways that led to increased VEGF expression and angio-
genesis in the form of CNV.
We delved into the signaling mechanisms surrounding 
TNF-α-induced intracellular ROS in regulating VEGF 
expression in the RPE. We report a mechanism in which the 
inflammatory cytokine, TNF-α, acting through NADPH 
oxidase-generated ROS and subsequent β-catenin transcrip-
tional activation induced an increase in VEGF expression in 
RPE cells. The role of Wnt/β-catenin in neovascular AMD 
Figure 6. TNF-α upregulates VEGF 
by mediating ROS-dependent tran-
scriptional activation of β-catenin. 
Representative western blots of (A) 
β-catenin and (B) vascular endothe-
lial growth factor (VEGF) in RPE 
cells pretreated with JW67 (20 
µM) or XAV939 (1 µM) or control 
dimethyl sulfoxide (DMSO) for 30 
min before incubation with tumor 
necrosis factor alpha (TNF-α; 20 
ng/ml) for an additional 1, 3, or 
6 h. C: Coimmunoprecipitation 
of β-catenin and T cell factor 1 
(TCF1) in RPE cells pretreated 
with apocynin (APO, 100 µM) or 
XAV939 or control DMSO for 30 
min (representative blot). D: Coim-
munoprecipitation of β-catenin and 
TCF1 in RPE cells transfected with 
p22phox siRNA and incubated with 
TNFα (20 ng/ml) for 2 h (represen-
tative blot).
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has been proposed [5]. β-catenin has multiple cell functions; 
by interacting with cadherin, β-catenin is an adherens junc-
tion component, and β-catenin is also a component of the 
Wnt signaling pathway. Activated β-catenin translocates into 
the nucleus and associates with transcription factors from 
the TCF/Lef family to drive transcription of Wnt/β-catenin 
target genes [28]. In cultured RPE cells, TNF-α increased 
β-catenin expression and led to a physical association with 
TCF1, whereas quenching ROS by apocynin or knockdown 
of the NADPH oxidase subunit, p22phox, inhibited this 
association of β-catenin with TCF1. These results provide 
evidence that TNF-α-mediated Wnt/β-catenin activation was 
triggered by intracellular ROS. Inhibition of β-catenin by the 
Wnt/β-catenin inhibitor, XAV939, but not JW67, reduced 
TNF-α-induced VEGF upregulation in the RPE, suggesting 
TNF-α induced VEGF upregulation required ROS-dependent 
β-catenin signaling. JW67 and XAV939 efficiently inhibit 
transcriptional activity of β-catenin in tumor cells by binding 
tankyrase1/2 enzymes that stimulate β-catenin degradation. 
The different effects of JW67 and XAV939 in inhibiting 
TNF-α-mediated β-catenin expression in the RPE may poten-
tially be due to different binding affinities to tankyrase1/2 
or because of different expression levels of tankyrase1/2 
in RPE cells compared to tumor cells [22]. NF-ҡB is a key 
transcriptional factor in response to TNF-α. In cultured RPE 
cells, TNF-α activated NF-ҡB; however, inhibition of NF-ҡB 
did not affect VEGF expression induced by TNF-α. Our data 
were consistent with findings from another study [18], in 
which TNF-α upregulated VEGF in a non-polarized RPE cell 
monolayer via an NF-ҡB-independent mechanism.
In summary, we demonstrated that TNF-α contributed 
to CNV formation by upregulating VEGF expression in RPE 
cells involving β-catenin transcriptional activation (Figure 7). 
Our results taken together provide evidence for interactions 
among inflammatory, oxidative, and angiogenic mechanisms 
and may have implications in neovascular AMD. Inhibition 
of TNF-α may be another means of reducing or inhibiting 
the pathologic effects of VEGF in the development of CNV.
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Figure 7. Diagram illustrating the 
hypothetical signaling pathway 
and interactions in inflammation, 
oxidative stress, and angiogenesis-
regulated VEGF expression and 
CNV formation via activation of 
β-catenin (TNFR – TNFα receptor). 
Refer to the text for details.
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